



EACCME EVENT LEE19-02036

Virtual interactive course

Orchestrated out of Les Pensières, Center for Global Health

Veyrier-du-Lac – France

May 9-27, 2021

FINAL COURSE PROGRAM

Organized by

The Mérioux Foundation
and the University of Geneva

With the co-sponsorship of

-
- Bill & Melinda Gates Foundation
 - Centers for Disease Control and Prevention (CDC)
 - European Centre for Disease Prevention and Control (ECDC)
 - European & Developing Countries Clinical Trials Partnership (EDCTP)
 - European Society for Paediatric Infectious Diseases (ESPID)
 - Johns Hopkins Bloomberg School of Public Health
 - National Foundation for Infectious Diseases (NFID)
 - National Institutes of Health (NIAID, NIH) and Fogarty International Center
 - World Health Organization



**UNIVERSITÉ
DE GENÈVE**



INTERACTIVE VIRTUAL ADVANCED COURSE OF VACCINOLOGY - 2021

Due to the COVID crisis, this 21st edition of ADVAC will be held in a virtual interactive mode. As the course will be orchestrated out of Les Pensières Centre for Global Health, Paris time is used.

SUNDAY 9 MAY 2021		
13:00-13:10	Opening	Alain Mérieux, President, Fondation Mérieux
13:10-13:30	Objectives of the Course and briefing	Philippe Duclos, Director, ADVAC
	SESSION 1a - THE MULTIFACETED NATURE OF VACCINOLOGY	Chairperson: Adam Finn, University of Bristol, UK
13:30-13:55	Opening Lecture: How to develop a new program of immunization	David Salisbury, former Director of Immunisation, Department of Health, UK, Centre on Global Health Security, UK
13:55-14:15	Discussion	
14:15-15:00	Break	
15:00-17:00	Self-presentation of individual participants (background, interests in life...) and support/facilitation team in Les Pensières	



**UNIVERSITÉ
DE GENÈVE**



FONDATION MÉRIEUX



MONDAY 10 MAY 2021		
	SESSION 1a - THE MULTIFACETED NATURE OF VACCINOLOGY (ctd.)	Chairperson: Adam Finn, University of Bristol, UK
13:00-13:25	Access to vaccination in GAVI eligible countries and at global level	Aurelia Nguyen, GAVI Alliance, Geneva
13:25-13:45	Discussion	
13:45-14:10	A global perspective on the regulation of vaccines	Norman Baylor, Biologics Consulting Inc., USA
14:10-14:30	Discussion	
14:30-14:55	The challenge of malaria vaccines and of their potential introduction	Mary Hamel, WHO, Geneva
14:55-15:15	Discussion	
15:15-16:00	Break	
16:00-17:30	Session 1b: Special lectures from Industry	Chairperson: Adam Finn, University of Bristol, UK
17:30-18:30	Debate on mandatory vs voluntary vaccination	Chaired by Hanna Nohynek, National Institute for Health and Welfare, Helsinki Adam Finn, University of Bristol, UK and Saad Omer, Yale University, USA



**UNIVERSITÉ
DE GENÈVE**



FONDATION MÉRIEUX



TUESDAY 11 MAY 2021		
	SESSION 2 - HOW VACCINES WORK	Chairperson: Daniel Pinschewer, University of Basel, Switzerland
13:00-13:25	How are vaccine responses elicited? What a vaccinologist should know about the basic aspects of immunological responses (a) B-cell responses	Claire-Anne Siegrist, University of Geneva
13:25-13:45	Discussion	
13:45-14:10	What a vaccinologist should know about the basic aspects of immunological responses (b) T-cell responses	Claire-Anne Siegrist, University of Geneva
14:10-14:30	Discussion	
14:30-14:55	Use and limitations of correlates of immunity in vaccinology	Andrew Pollard, University of Oxford, UK
14:55-15:15	Discussion	
15:15-16:00	Break	
16:00-16:25	Vaccines and mucosal immunity	Adam Finn, University of Bristol, UK
16:25-16:45	Discussion	
16:45-17:30	Vaccines and immunological memory Quiz and general discussion	Claire-Anne Siegrist, University of Geneva
17:30-17:55	Immunological memory	Rafi Ahmed, Emory University, USA
17:55-18:15	Discussion	



**UNIVERSITÉ
DE GENÈVE**



FONDATION MÉRIEUX



WEDNESDAY 12 MAY 2021		
	SESSION 2 - HOW VACCINES WORK (Ctd)	Chairperson: Daniel Pinschewer, University of Basel, Switzerland
13:00-13:25	Advances in vaccine and immunization technologies	Cristina Casetti, NIH-NIAID, USA
13:25-13:45	Discussion	
	SESSION 3 - DECISION-MAKING IN VACCINE RESEARCH AND PRECLINICAL DEVELOPMENT	Chairperson: Emily Erbelding, Director, DMID, National Institutes of Health (NIH), USA
13:45-14:10	How do vaccines cause adverse events?	Saad Omer, Yale University, New Haven, USA
14:10-14:30	Discussion	
14:30-14:55	Vaccine adjuvants	Martin Friede, WHO, Geneva
14:55-15:15	Discussion	
15:15-16:00	Break	
16:00-16:25	From pre-clinical research to vaccine development: Examples of go-no-go decisions	Veronica Gambillara, GlycoEra AG, Switzerland
16:25-16:45	Discussion	
16:45-17:10	The complexity of quality control in vaccine manufacturing	Philippe Juvin, Sanofi Pasteur, Lyon, France
17:10-17:30	Discussion	
17:30-18:30	Regulatory considerations A round-table debate	Chair: Emily Erbelding, Director, DMID/NIAID, NIH, USA Norman Baylor, Biologics Consulting Group, Inc., USA, Pieter Neels, Vaccine-advice, Belgium, Saeedeh Fakhrzadh, Food and Drug Administration, Iran, Ozzie Berger, GSK and David Greenberg, Sanofi Pasteur



**UNIVERSITÉ
DE GENÈVE**



FONDATION MÉRIEUX



THURSDAY 13 MAY 2021		
	SESSION 4 - ASSESSING VACCINES IN CLINICAL TRIALS (I)	Chairperson: Hanna Nohynek, National Institute for Health and Welfare, Helsinki, Finland
13:00-13:25	Clinical trials: an overview of issues to be considered	Myron Levine, University of Maryland, USA
13:25-13:45	Discussion	
13:45-14:10	Introduction to statistical aspects of clinical trials 1- Defining sample size	Peter Smith, London School of Hygiene and Tropical Medicine, UK
14:10-14:30	Discussion	
14.30-14.55	Assessing herd protection and vaccine effectiveness (and use for licensure)	John Clemens, International Centre for Diarrheal Disease Research, Bangladesh (icddr,b)
14:55-15:15	Discussion	
15:15-16:00	Break	
16:00-17:45	How to design, recruit volunteers for, and analyze the results of selected phase II trials Small group exercise 1: Seven groups- Themes: Group 1 S. aureus Group 2 Ebola Group 3 Dengue Group 4 GBS Group 5 RSV Group 6 Men B Group 7 Coronavirus	Facilitators: Veronica Gambillara Pieter Neels Norman Baylor Edwin Asturias Kari Johansen Adam Finn Emily Erbeling
17:45-18:25	THE 5 th LAMBERT LECTURE Interactions between the immune system and the microbiota	Yasmine Belkaid, NIH/NIAID, USA
18:25-18:45	Discussion	



**UNIVERSITÉ
DE GENÈVE**



FONDATION MÉRIEUX



FRIDAY 14 MAY 2021		
	SESSION 5 - VACCINE SAFETY - ASSESSMENT OF ADVERSE EFFECTS	Chairperson: Kari Johansen, Formerly ECDC
13:00-13:25	Lessons from previous adverse events of vaccination and assessment of causal relationships	Madhav Balakrishnan, WHO, Geneva
13:25-13:45	Discussion	
13:45-14:10	Vaccination and immune-mediated diseases	Paul-Henri Lambert, University of Geneva
14:10-14:30	Discussion	
14:30-14:55	Population-based post-licensure surveillance	Nick Andrews, Public Health England, UK
14:55-15:15	Discussion	
15:15-15:55	Break	
	SESSION 6 – ASSESSING VACCINES IN CLINICAL TRIALS (II)	Chairperson: Hanna Nohynek, National Institute for Health and Welfare, Helsinki, Finland
15:55-16:20	Clinical trials: role of a Data Safety Monitoring Board (DSMB) (with several examples of intervention)	Penny Heaton, Bill & Melinda Gates Medical Research Institute, Seattle, USA
16:20-16:40	Discussion	
16:40-17:05	Introduction to statistical aspects of clinical trials 2- Statistical assessment and reporting of phase 3 trials	Peter Smith, London School of Hygiene and Tropical Medicine, UK
17:05-17:25	Discussion	
17:25-19:10	Small group exercise 2: Designing and analyzing the results of selected phase 3 trials	
	Introduction to the Group Work Exercise	Hanna Nohynek, National Institute for Health and Welfare, Helsinki, Finland
	Seven groups	Facilitators: Nick Andrews, Brad Gessner, Penny Heaton, Kari Johansen, Pieter Neels, Peter Smith



**UNIVERSITÉ
DE GENÈVE**



FONDATION MÉRIEUX



SATURDAY 15 MAY 2021

	SESSION 5 - VACCINE SAFETY - ASSESSMENT OF ADVERSE EFFECTS (Ctd)	Chairperson: Kari Johansen, Formerly ECDC
13:00-13:25	Vaccination and narcolepsy	Hanna Nohynek, National Institute for Health and Welfare, Helsinki, Finland
13:25-13:45	Discussion	
13:45-14:10	Immunization safety in low and middle income country vaccination programs	Philippe Duclos, ADVAC
14:10-14:30	Discussion	
14:30-14:55	Addressing vaccine hesitancy	Noni MacDonald, Dalhousie University, Halifax, Canada
14:55-15:15	Discussion	
15.15-16:00	Break	
	SESSION 7 - ETHICAL ISSUES Ethical considerations related to vaccine trials and implementation of vaccines in organized programs - available principles, guidelines and frameworks	Chairperson: Kari Johansen, Formerly ECDC
16:00-16:25	Principles, guidelines and frameworks for ethical considerations in clinical trials of vaccines	Catherine Slack, University of KwaZulu-Natal, South Africa
16:25-16:45	Discussion	
16:45-17:10	Applied ethics in immunization programs and practice	Noni MacDonald, Dalhousie University, Halifax, Canada
17:10-17:30	Discussion	
17:30-19:15	Small group exercise 3: Ethical considerations in COVID vaccine trials	Coordinated by Kari Johansen, Betty Dodet (Dodet Bioscience, France) and Catherine Slack
	Seven groups	Facilitators: Catherine Slack, Betty Dodet, Noni MacDonald, Kari Johansen, Pieter Neels, Adam Finn, Romina Libster



**UNIVERSITÉ
DE GENÈVE**



FONDATION MÉRIEUX



MONDAY 17 MAY 2021

SESSION 8 - INTRODUCING NEW VACCINES INTO VACCINATION PROGRAMMES		Chairperson: Anna Durbin, Johns Hopkins B. School of Public Health, Baltimore, USA
13:00-13:25	Disease burden and the public health value of vaccines	Annelies Wilder-Smith, Consultant, WHO
13:25-13:45	Discussion	
13:45-14:10	Health economics (including modelling) as a tool in analyzing vaccine policy options	Mark Miller, NIH, USA
14:10-14:30	Discussion	
14:30-14:55	Challenges and solutions in making evidence-based national vaccination policies and recommendations	Philippe Duclos, ADVAC
14:55-15:15	Discussion	
15:15-16:00	Break	
16:00-16:25	Dengue vaccines	Anna Durbin, Johns Hopkins B. School of Public Health, Baltimore, USA
16:25-16:45	Discussion	
16:45-17:10	Response to polysaccharide and conjugate vaccines: basic aspects	David Goldblatt, University College London, UK
17:10-17:30	Discussion	
17:30-17:55	Pneumococcal conjugate vaccines: Efficacy and limitations of available vaccines and existing and potential vaccination strategies	Ron Dagan, Soroka Medical Center, Beer Sheva, Israel Keith Klugman, Bill & Melinda Gates Foundation, USA
17:55-18:15	Discussion	
18:15-19:15	Debate: Does a vaccine have to protect against a VPD that kills to matter to politicians and parents?	Chair: Ron Dagan, Soroka Medical Center, Beer Sheva, Israel Presenters: Keipp Talbot, Vanderbilt University, USA, Kari Johansen, Formerly ECDC, Mark Miller NIH, USA



**UNIVERSITÉ
DE GENÈVE**



FONDATION MÉRIEUX



TUESDAY 18 MAY 2021

	SESSION 8 - INTRODUCING NEW VACCINES INTO VACCINATION PROGRAMMES (Ctd)	Chairperson: Roger Glass, Fogarty International Centre, NIH														
13:00-13:25	HPV vaccines	Margaret Stanley, Cambridge University, UK														
13:25-13:45	Discussion															
13:45-14:10	Meningococcal vaccines	Ray Borrow, Public Health England, UK														
14:10-14:30	Discussion															
14:30-14:55	Vaccine responses and efficacy in the elderly (including the specific example of the Zoster vaccine)	Keipp Talbot, Vanderbilt University, USA														
14:55-15:15	Discussion															
15:15-15:55	Break															
15:55-16:20	Population biology of bacterial pathogens and its importance for vaccination strategies.	Richard Moxon, Oxford University, UK														
16:20-16:40	Discussion															
16:40-17:05	Success and challenges with rotavirus and norovirus vaccines	Umesh Parashar, Centers for Disease Control, Atlanta, USA														
17:05-17:25	Discussion															
17:25-18:55	<p>Small group exercise 4: Decision-making for the evaluation and impact assessment of new vaccines introduced in selected countries: safety and effectiveness</p> <p>Objective: To learn what facts are needed in a decision-making process and how other factors influence the outcome</p> <p>Seven groups- Themes:</p> <table border="0"><tr><td>Group 1</td><td>Rotavirus</td></tr><tr><td>Group 2</td><td>HPV</td></tr><tr><td>Group 3</td><td>Coronavirus LMIC</td></tr><tr><td>Group 4</td><td>Coronavirus HIC</td></tr><tr><td>Group 5</td><td>Malaria</td></tr><tr><td>Group 6</td><td>Shingles</td></tr><tr><td>Group 7</td><td>Tdap</td></tr></table>	Group 1	Rotavirus	Group 2	HPV	Group 3	Coronavirus LMIC	Group 4	Coronavirus HIC	Group 5	Malaria	Group 6	Shingles	Group 7	Tdap	<p>Organized by Kari Johansen, Hanna Nohynek and Edwin Asturias</p> <p>Facilitators: Umesh Parashar & Roger Glass Mark Miller Brad Gessner & Hanna Nohynek Kari Johansen Kathy Neuzil Keipp Talbot Janet Englund</p>
Group 1	Rotavirus															
Group 2	HPV															
Group 3	Coronavirus LMIC															
Group 4	Coronavirus HIC															
Group 5	Malaria															
Group 6	Shingles															
Group 7	Tdap															



UNIVERSITÉ
DE GENÈVE



FONDATION MÉRIEUX

WEDNESDAY 19 MAY 2021

	SESSION 9 - SELECTING APPROPRIATE VACCINATION STRATEGIES	Chairperson: Janet Englund, Children's Hospital and Regional Medical Center, Seattle, USA
13:00-13:25	Vaccination in early life	Claire-Anne Siegrist, University of Geneva
13:25-13:45	Discussion	
13:45-14:10	Impact of vaccination on disease epidemiology	Roy Anderson, Director, London Centre for Neglected Tropical Disease Research, Imperial College, London
14:10-14:30	Discussion	
14:30-14:55	Vaccination and pregnancy: Scientific basis, main issues and applications	Janet Englund, Children's Hospital and Regional Medical Center, Seattle, USA
14:55-15:15	Discussion	
15:15-16:00	Break	
16:00-18:00	Parallel working group sessions	
	1. National decision-making for immunization programmes	Christoph Steffen, WHO and Philippe Duclos, ADVAC
	2. Clinical vaccinology: patients' problem solving	Alessandro Diana and Christiane Eberhardt, University of Geneva
	3. New approaches towards vaccination e-registries	Carolina Danovaro, WHO Geneva, Kari Johansen, Formerly ECDC , Sweden, and Julia Stowe, Public Health England, UK
	4. Cold Chain management	Suleymane Kone, WHO Geneva and Collins Tabu, Immunization Manager, Kenya
18:00-18:25	Vaccination in immuno-compromised individuals, including HIV positive patients	Janet Englund, Children's Hospital and Regional Medical Center, Seattle, USA
18:25-18:45	Discussion	



**UNIVERSITÉ
DE GENÈVE**



FONDATION MÉRIEUX

THURSDAY 20 MAY 2021

	SESSION 9 - SELECTING APPROPRIATE VACCINATION STRATEGIES (ctd)	Chairperson: Janet Englund, Children's Hospital and Regional Medical Center, Seattle, USA
13:00-13:25	Non-specific effects of vaccines	Nigel Curtis, The Royal Children's Hospital, Melbourne
13:25-13:45	Discussion	
13:45-14:10	Vaccination schedules: Past, present and future - is there some rationale?	Edwin Asturias, Children's Hospital Colorado, USA
14:10-14:30	Discussion	
14:30-15:05	Break	
15:05-15:30	Influenza biology, new vaccines and vaccination strategies for different age groups	Kathy Neuzil, Center for Vaccine Development, University of Maryland, Baltimore, USA
15:30-15:50	Discussion	
	SESSION 10: VACCINES UNDER DEVELOPMENT	Chairperson: Edwin Asturias, Children's Hospital Colorado, USA
15:50-16:30	History of vaccines and vaccination	Stanley Plotkin, University of Pennsylvania, USA
16:30-16:50	Discussion	
	Special lecture: THE 13TH PLOTKIN LECTURE	
16:50-17:00	Introduction and Chair	Edwin Asturias, Children's Hospital Colorado, USA
17:00-17:40	Yellow fever	Thomas Monath, Crozet BioPharma LLC
17:40:18:00	Discussion	
18:00-18:25	Vaccines against epidemic and orphan diseases: How new technologies can change vaccine development	Barney Graham, Vaccine Research Center, NIAID, NIH, Bethesda, USA
18:25-18:45	Discussion	



**UNIVERSITÉ
DE GENÈVE**



FONDATION MÉRIEUX

FRIDAY 21 MAY 2021		
	SESSION 10 - VACCINES UNDER DEVELOPMENT (Ctd)	Chairperson: Edwin Asturias, Children's Hospital Colorado, USA
13:00-13:25	Available COVID vaccines with focus on effectiveness and safety, what we know and what we do not know	Melanie Saville, CEPI, UK
13:25-13:45	Discussion	
13:45-14:10	HIV vaccines	Brigitte Autran, INSERM, France
14:10-14:30	Discussion	
14:30-14:55	Challenges and prospects for new tuberculosis vaccines	Helen McShane, University of Oxford, UK
14:55-15:15	Discussion	
15:15-16:00	Break	
16:00-16:25	Global challenges for pertussis vaccines	Kathy Edwards, Vanderbilt Vaccine Research Program, USA
16:25-16:45	Discussion	
	SESSION 11 - OUTBREAKS' CONTROL: ELIMINATION AND ERADICATION STRATEGIES	Chairperson: Stanley Plotkin, University of Pennsylvania, USA
16:45-17:10	Immunization coverage gaps: overcoming the chronic challenges	Kate O'Brien, WHO, Geneva
17:10-17:30	Discussion	
17:30-17:55	Polio	Ananda Bandyopadhyay, Bill & Melinda Gates Foundation, USA
17:55-18:15	Discussion	
18:15-18:40	Diphtheria, measles and rubella	Ann Lindstrand, WHO, Switzerland
18:40-19:00	Discussion	



**UNIVERSITÉ
DE GENÈVE**



FONDATION MÉRIEUX



SATURDAY 22 MAY 2021

	SESSION 10 - VACCINES UNDER DEVELOPMENT (Ctd)	Chairperson: Philippe Duclos, University of Geneva
13:00-13:25	Cancer vaccines	Olivier Michielin, Centre Hospitalier Universitaire Vaudois, Switzerland
13:25-13:45	Discussion	
	SESSION 12 - RECAP	Chairperson: Philippe Duclos, University of Geneva
13:45-14:30	Answers to important questions received beforehand from participants	Panel session: Norman Baylor; Alexandro Cravioto, Chair of SAGE; Arnaud Didierlaurent, University of Geneva; Roger Glass; Ilesh Jani, National Institute of Health, Mozambique; Romina Libster; Robin Nandy, UNICEF; Stanley Plotkin, and additional faculty members selected based on key questions raised by the participants
14:30-15:10	Highlights from ADVAC 2021	Romina Libster, Fundación INFANT/ National Scientific and Technical Research Council/ Vanderbilt University



**UNIVERSITÉ
DE GENÈVE**



FONDATION MÉRIEUX

MONDAY 24 MAY 2021

SESSION 13 - FACING THE MEDIA AND ENSURING VIRTUAL IMPACT: WHAT THE VACCINOLOGIST SHOULD KNOW IN THE CONTEXT OF VACCINE HESITANCY AND ANTI-IMMUNIZATION LOBBY (SCHEDULED IN THREE SUBGROUPS ACCORDING TO DIFFERENT TIME ZONES)

Chairperson: Philippe Duclos, University of Geneva

09:00-11:00 or
14:00-16:00 or
18:00-20:00

FIRST PART: Interactive session
Introduction to media dynamics: How to best deliver vaccinology-related messages to different interest groups

Deborah Hall, Broadcaster and Media Affairs Consultant, London, UK



UNIVERSITÉ
DE GENÈVE



FONDATION MÉRIEUX

TUESDAY 25 MAY 2021

13:00-15:00

Debate: From ideas to implementation: The realities of funding for vaccine research and development (RELATES TO SESSION 3)

Emily Erbelding, DMID, NIH, USA, (Chairperson), Veronica Gambillara, GlycoEra AG, Switzerland, Penny Heaton, Bill & Melinda Gates Medical Research Institute, Seattle (USA) and selected ADVAC participants



UNIVERSITÉ
DE GENÈVE



FONDATION MÉRIEUX

WEDNESDAY 26 MAY 2021

13:00-14:30	Debate: Dealing with human challenge studies (RELATES TO SESSION 4)	Chairperson: Penny Heaton, Bill & Melinda Gates Medical Research Institute, Seattle, USA Introduction on Challenge trials, Penny Heaton 20 mins. Debate between Joris Vandeputte, IABS and Pieter Neels, Vaccine-advice, Belgium
14:30-16:30	Alumni presentations	Chairperson: Philippe Duclos Ann Lindstrand, WHO Shabir Madhi, University of the Witwatersrand, South Africa Kamel Senouci, Bill & Melinda Gates Foundation



**UNIVERSITÉ
DE GENÈVE**



FONDATION MÉRIEUX

THURSDAY 27 MAY 2021

SESSION 13 - FACING THE MEDIA AND ENSURING VIRTUAL IMPACT: WHAT THE VACCINOLOGIST SHOULD KNOW IN THE CONTEXT OF VACCINE HESITANCY AND ANTI-IMMUNIZATION LOBBY

Chairperson: Philippe Duclos, University of Geneva

09:00-11:00
or
14:00-16:00
or
18:00-20:00

SECOND PART: Interactive session
Introduction to media dynamics: How to best deliver vaccinology-related messages to different interest groups (continued)

Deborah Hall, Broadcaster and Media Affairs Consultant,
London, UK



**UNIVERSITÉ
DE GENÈVE**



FONDATION MÉRIEUX



SESSION 1b - Special lectures from Industry

16:00-16:25	Role of LMIC vaccine industry for meeting global needs	Suresh Jadhav, Executive Director, Serum Institute of India, Pune, India
16:25-16:45	Discussion	
16:45-17:10	Development and production of vaccines for global use: the role of vaccine industry	Luis Jodar, Senior Vice President and Chief Medical Officer, Vaccines, Pfizer Inc. USA
17:10-17:30	Discussion	



UNIVERSITÉ
DE GENÈVE



FONDATION MÉRIEUX